Chronic Rheumatic Diseases: Clinical Evidence with Piroxicam--Cyclodextrin

Author: Serni U.

Source: Clinical Drug Investigation, Volume 19, Supplement 2, 2000 , pp. 51-54(4)

Publisher: Adis International

Abstract:

Nonsteroidal anti-inflammatory drugs (NSAIDs) play an important role in alleviating pain, restoring function and improving quality of life in patients with chronic rheumatic diseases. Unfortunately, use of NSAIDs for long periods is associated with an increased risk of gastrointestinal adverse effects. Piroxicam--cyclodextrin is a new NSAID which is absorbed rapidly and thus achieves an early analgesic effect. A second potential advantage of more rapid absorption is that the drug is less likely to irritate the gastrointestinal mucosa and cause local adverse effects. Indeed, clinical studies of long term use of piroxicam--cyclodextrin have shown that this agent is at least as effective as other NSAIDs, with good gastrointestinal tolerability. This favourable risk-benefit profile of piroxicam--cyclodextrin supports its use in the long term treatment of chronic rheumatic diseases.

Keywords: Diclofenac, therapeutic use; Nonsteroidal antiinflammatories, therapeutic use; Piroxicam, therapeutic use; Piroxicam beta cyclodextrin, therapeutic use; Rheumatic disorders, treatment

Language: English

Document Type: Review article

Affiliations: 1: Rheumatology Division, Istituto Ortopedico Toscano, Florence, Italy *

Publication date: 2000-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Serni U.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers